ScreenerHero

ZNTL Zentalis Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · zentalis.com
2.550USD-4.49%Mkt Cap: 250.21M $P/E: —

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenose…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap250.21M USD
Enterprise Value54.45M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-137.06M USD
Revenue/Share—
Last Price2.550 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees106
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.44
PEG—
EV/EBITDA-0.36
EV/Revenue—
P/S—
P/B1.33
EPS (TTM)-1.96
EPS (Forward)-1.86
52W Range
1.21223% of range6.950
52W High6.950 USD
52W Low1.212 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-63.39%
ROA-47.43%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-125.25M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-31.75%
Net Debt-136.92M USD
Net Debt/EBITDA0.91
Balance Sheet
Debt/Equity0.17
Current Ratio4.82
Quick Ratio4.64
Book Value/Sh2.00 USD
Cash/Share2.44 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.333 USD
Upside (mean)+187.6%
Target Range5.000 USD – 10.00 USD
5.000+187.6% to mean10.00
# Analysts9
Ownership
Shares Out.98.12M
Float56.64M
Insiders21.85%
Institutions50.88%
Short Interest
Short Ratio5.0d
Short % Float5.71%
Short % Out.4.88%
Shares Short4.79M
Short (prev mo.)5.97M
Technical
SMA 503.722 (-31.5%)
SMA 2003.424 (-25.5%)
Beta1.94
S&P 52W Chg16.45%
Avg Vol (30d)1.26M
Avg Vol (10d)1.81M
Technical Indicators
RSI (14)32.1
MACD-0.3545
MACD Signal-0.3534
MACD Hist.-0.0011
BB Upper4.059 USD
BB Middle3.063 USD
BB Lower2.068 USD
BB Width64.97%
ATR (14)0.2265 USD
Vol Ratio (20d)0.60x